Estrogen-responsive finger protein as a new potential biomarker for breast cancer

Clinical Cancer Research

Volumn 11, Issue 17, 2005, Pages 6148-6154

  Suzuki, Takashi ^a   Urano, Tomohiko ^b   Tsukui, Tohru ^c   Horie Inoue, Kuniko ^c   Moriya, Takuya ^a   Ishida, Takanori ^a   Muramatsu, Masami ^c   Ouchi, Yasuyoshi ^b   Sasano, Hironobu ^a   Inoue, Satoshi ^b,c  

^a TOHOKU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c SAITAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR ALPHA; ESTROGEN RESPONSIVE FINGER PROTEIN; MESSENGER RNA; PROTEIN; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; CANCER GRADING; CANCER GROWTH; CANCER SURVIVAL; CELL GROWTH; CLINICAL ARTICLE; FEMALE; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN FAMILY;

14-3-3 PROTEINS; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; DNA-BINDING PROTEINS; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; MIDDLE AGED; NEOPLASM INVASIVENESS; PROGNOSIS; RECEPTORS, ESTROGEN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SURVIVAL RATE; TRANSCRIPTION FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 24344471715     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-05-0040     Document Type: Article

References (22)

1. Ali S, Coombes RC. Endocrine-responsive breast cancer and strategies for combating resistance. Nat Rev Cancer 2002;2:101-12.
2. Jordan VC. Fourteenth Gaddum Memorial Lecture. A current view of tamoxifen for the treatment and prevention of breast cancer. Br J Pharmacol 1993;110: 507-17.
3. Inoue S, Orimo A, Hosoi T, et al. Genomic binding-site cloning reveals an estrogen-responsive gene that encodes a RING finger protein. Proc Natl Acad Sci U S A 1993;90:11117-21.
4. Orimo A, Inoue S, Ikeda K, Noji S, Muramatsu M. Molecular cloning, structure, and expression of mouse estrogen-responsive finger protein Efp. Co-localization with estrogen receptor mRNA in target organs. J Biol Chem 1995;270:24406-13.
5. Ikeda K, Orimo A, Higashi Y, Muramatsu M, Inoue S. Efp as a primary estrogen-responsive gene in human breast cancer. FEBS Lett 2000;472:9-13.
6. Muramatsu M, Inoue S. Estrogen receptors: how do they control reproductive and nonreproductive functions? Biochem Biophys Res Commun 2000; 270:1-10.
7. Orimo A, Inoue S, Minowa O, et al. Underdeveloped uterus and reduced estrogen responsiveness in mice with disruption of the estrogen-responsive finger protein gene, which is a direct target of estrogen receptor a. Proc Natl Acad Sci U S A 1999;96:12027-32.
8. Urano T, Saito T, Tsukui T, et al. Efp targets 14-3-3σ for proteolysis and promotes breast tumour growth. Nature 2002;417:871-5.
9. Thomson SD, Ali S, Pickles L, et al. Analysis of estrogen-responsive finger protein expression in benign and malignant human breast. Int J Cancer 2001;91: 152-8.
10. Suzuki T, Nakata T, Miki Y, et al. Estrogen sulfotransferase and steroid sulfatase in human breast carcinoma. Cancer Res 2003;63:2762-70.
11. Allred DC, Harvey JM, Berardo M, Clark GM. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol 1998;11:155-68.
12. Emmert-Buck MR, Bonner RF, Smith PD, et al. Laser capture microdissection. Science 1996;274: 998-1001.
13. Niino YS, Irie T, Takaishi M, et al. PKCθ II, a new isoform of protein kinase C specifically expressed in the seminiferous tubules of mouse testis. J Biol Chem 2001;276:36711-7.
14. Ikeda K, Inoue S, Orimo A, et al. Multiple regulatory elements and binding proteins of the 5′-flanking region of the human estrogen-responsive finger protein (efp) gene. Biochem Biophys Res Commun 1997;236: 765-71.
15. Dowlatshahi K, Fan M, Snider HC, Habib FA. Lymph node micrometastases from breast carcinoma: reviewing the dilemma. Cancer 1997;80:1188-97.
16. Suzuki T, Moriya T, Ishida T, Ohuchi N, Sasano H. Intracrine mechanism of estrogen synthesis in breast cancer. Biomed Pharmacother 2003;57: 460-2.
17. 2/M progression. Mol Cell 1997;1:3-11.
18. Chan TA, Hermeking H, Lengauer C, Kinzler KW, Vogelstein B. 14-3-3σ is required to prevent mitotic catastrophe after DNA damage. Nature 1999;401: 616-20.
19. Ferguson AT, Evron E, Umbricht CB, et al. High frequency of hypermethylation at the 14-3-3σ locus leads to gene silencing in breast cancer. Proc Natl Acad Sci U S A 2000;97:6049-54.
20. Umbricht CB, Evron E, Gabrielson E, Ferguson A, Marks J, Sukumar S. Hypermethylation of 14-3-3σ (stratifin) is an early event in breast cancer. Oncogene 2001;20:3348-53.
21. Simooka H, Oyama T, Sano T, Horiguchi J, Nakajima T. Immunohistochemical analysis of 14-3-3σ and related proteins in hyperplastic and neoplastic breast lesions, with particular reference to early carcinogenesis. Pathol Int 2004;54:595-602.
22. Moreira JM, Ohlsson G, Rank FE, Celis JE. Down-regulation of the tumor suppressor protein 14-3-3σ is a sporadic event in cancer of the breast. Mol Cell Proteomics 2005;4:555-69.